Liberate Medical Secures $6.2M in Series B Financing
Series B Co-Led by a Large Strategic Investor and Scientific Health Development to Support the Pivotal Clinical Trial of the VentFree® Respiratory Muscle Stimulator
CRESTWOOD, Ky.--(BUSINESS WIRE)-- Liberate Medical, an emerging leader in the development of novel non-invasive neurostimulation devices focused on transforming respiratory care, announced today the successful closure of its $6.2M Series B financing round. The funding was co-led by a large strategic investor and Scientific Health Development, who will both join Liberate Medical’s Board, solidifying Liberate Medical's position as a leading innovator in respiratory and critical care.